Safety evaluation of trabectedin in treatment of soft-tissue sarcomas

Bibliography

• Italiano A, Mathoulin-Pelissier S, Le Cesne A, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117(5):1049-54
   PubMed Web of Science ®Google Scholar
• van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17(1):150-7
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38(18):2397-406
   PubMed Web of Science ®Google Scholar
• Leahy M, Garcia Del Muro X, Reichardt P, et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. TheSArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann Oncol 2012;23(10):2763-70
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Gelderblom H. New systemic therapy options for advanced sarcomas. Curr Treat Options Oncol 2012;13(3):306-17
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9(8):2157-63
   PubMed Web of Science ®Google Scholar
• Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 2008;19(9):3969-81
   PubMed Web of Science ®Google Scholar
• Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007;104(32):13062-7
   PubMed Web of Science ®Google Scholar
• Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008;44(4):609-18
   PubMed Web of Science ®Google Scholar
• Casado JA, Río P, Marco E, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7(5):1309-18
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23(2):249-62
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22(5):890-9
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22(8):1480-90
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23(3):576-84
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23(24):5484-92
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27(25):4188-96
   PubMed Web of Science ®Google Scholar
• Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013;24(6):1703-9
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8(7):595-602
   PubMed Web of Science ®Google Scholar
• Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20(8):1439-44
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer 2012;48(16):3036-44
   PubMed Web of Science ®Google Scholar
• Gomez J, Lopez-Lazaro L, Guzman C, et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol 19:187-2000
   Google Scholar
• Lopez-Martin JA, Nieto A, Demetri GD, et al. Safety profile of ecteinascidin-743 (ET-743) in phase II clinical trials (CT) in adult patients with solid tumors [abstract 382]. Proc Am Soc Clin Oncol 2002;21:96a
   Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000773/WC500045836.pdf
   Google Scholar
• Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012;124(1):48-52
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol 2011;123(3):553-6
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Yovine A, Blay JY, et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs 2012;30(3):1193-202
   PubMed Web of Science ®Google Scholar
• Le Cesne A. 13 years of trabectedin, 5 years of Yondelis(®): what have we learnt? Expert Rev Anticancer Ther 2013;13(6 Suppl 1):s11-19
   Google Scholar
• Paz-Ares L, López-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012;30(2):729-40
   PubMed Web of Science ®Google Scholar
• Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42(10):1484-90
   PubMed Web of Science ®Google Scholar
• Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003;63(18):5902-8
   PubMed Web of Science ®Google Scholar
• Grosso F, D'Incalci M, Cartoafa M, et al. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol 2012;69(6):1557-65
   PubMed Web of Science ®Google Scholar
• Thariat J, Etienne-Grimaldi MC, Launay-Vacher V, et al. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. Cancer Chemother Pharmacol 2011;68(5):1363-7
   PubMed Web of Science ®Google Scholar
• Blay JY, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 2013;13:64
   PubMed Web of Science ®Google Scholar
• Hendifar AE, Chawla SP, Leahy MG, et al. Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS). J Clin Oncol 2013;31(Suppl):abstract 10517
   Google Scholar
• Available from: ClinicalTrials.gov identifier: NCT01189253
   Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28(19):3107-14
   PubMed Web of Science ®Google Scholar
• Blay JY, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008;14(20):6656-62
   PubMed Web of Science ®Google Scholar
• Available from: ClinicalTrials.gov identifier: NCT01104298
   Google Scholar
• Pautier P, Floquet A, Cupissol D, et al. LMS-02: a phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): first results in patients with u-LMS. J Clin Oncol 2013;31(Suppl):abstract 10505
   Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissuesarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27(19):3126-32
   PubMed Web of Science ®Google Scholar